William E. Paul Lecture
This annual lecture, begun in 2016 and part of the Wednesday Afternoon Lecture Series, honors the legacy of Dr. William E. Paul. Dr. Paul was the leader of the NIH immunology community and his career is without parallel in the field of immunology.
Human antibody responses to SARS-CoViD-2
Dr. Nussenzweig’s laboratory studies the molecular aspects of the immune system’s innate and adaptive responses using a combination of biochemistry, molecular biology, and genetics. For work on adaptive immunity, he focuses on B lymphocytes and antibodies to HIV-1, while his studies of innate immunity focus on dendritic cells. His work is leading to new antibody-based therapies for infections by HIV and the novel SARS-CoV-2 coronavirus, among other viruses.
Evolution of Adaptive Immunity in Vertebrates
Phylogenetic studies indicate that T cells and B cells have been constant companions in vertebrates for more than 500 million years. For antigen recognition, however, lymphocytes in the jawless vertebrates (lampreys and hagfish) use variable lymphocyte receptors that are composed of leucine-rich repeat sequences instead of immunoglobulin V(D)J and C domains. Convergent evolution may account for these alternative solutions to achieve specific adaptive immunity.
Standing on the shoulders of mice: adventures in human immunology
While inbred mice have been a very powerful model for analyzing the immune system, recent advances, both technological and conceptual, have begun to make direct studies of the human immune system possible. This is vitally important from a translational perspective, as mouse models of disease have not been as productive as hoped for in producing “actionable intelligence” with which to diagnose and treat patients.
The two faces of the IL-15- Janus Kinase-Stat system: implications for the immunotherapy of autoimmune diseases and cancer
Dr. Walmann will present the annual William Paul lecture. Dr. Waldmann defined the IL-2 receptor alpha and beta subunits using the daclizumab antibody he discovered, an antibody that is approved by the FDA. He co-discovered IL-15 and performed the first in-human clinical trial with this agent in patients with malignancy. Furthermore, Waldmann defined molecular abnormalities of the common gamma cytokine, Jak/Stat signaling pathway in HTLV-1 associated adult T-cell lymphoma and translated this discovery with a trial of a Jak inhibitor in patients with this disorder.
Stressed out: a novel approach to cancer immunotherapy
Dr. Glimcher is President and CEO of Dana-Farber Cancer Institute, Principal Investigator and Director of Dana-Farber/Harvard Cancer Center and the proposed Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medical College in New York City, and Provost for Medical Affairs of Cornell University. Prior to her work at Cornell, Dr.
The page was last updated on Friday, September 21, 2018 - 2:57pm
